While IDH mutational status and O6-methylguanine-DNA methyltransferase (MGMT) methylation are primary considerations in GBM treatment, GBM molecular subtypes are currently underemphasized in patient evaluation. The gene discussed is MGMT; the disease is glioblastoma.